Alan JD - NeuBase Therapeutics G Counsel
| NBSEDelisted Stock | USD 1.62 0.17 9.50% |
Insider
Alan JD is G Counsel of NeuBase Therapeutics
| Phone | 412 763 3350 |
| Web | https://www.neubasetherapeutics.com |
NeuBase Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4303) % which means that it has lost $0.4303 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9346) %, meaning that it created substantial loss on money invested by shareholders. NeuBase Therapeutics' management efficiency ratios could be used to measure how well NeuBase Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.NeuBase Therapeutics currently holds 6 M in liabilities with Debt to Equity (D/E) ratio of 0.2, which may suggest the company is not taking enough advantage from borrowing. NeuBase Therapeutics has a current ratio of 7.38, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about NeuBase Therapeutics' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Louise Kooij | NewAmsterdam Pharma | 48 | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Pr Sorek | Biomx Inc | N/A | |
| Corinne Savill | Cullinan Oncology LLC | 65 | |
| JD MBA | Monte Rosa Therapeutics | 46 | |
| Irena Konstantinova | Inventiva Sa | N/A | |
| Eran MD | Biomx Inc | N/A | |
| Silvia Buonamici | Monte Rosa Therapeutics | N/A | |
| Inbal BenjaminiElran | Biomx Inc | N/A | |
| John Castle | Monte Rosa Therapeutics | 53 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Jennifer Champoux | Monte Rosa Therapeutics | N/A | |
| Michael Cooreman | Inventiva Sa | 66 | |
| Phil JD | Monte Rosa Therapeutics | 45 | |
| Jennifer Michaelson | Cullinan Oncology LLC | 57 | |
| Jonathan JD | Compass Therapeutics | N/A | |
| Jean Volatier | Inventiva Sa | 60 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| JeanPaul MD | Inventiva Sa | N/A | |
| Pierre Broqua | Inventiva Sa | 62 | |
Management Performance
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 |
NeuBase Therapeutics Leadership Team
Elected by the shareholders, the NeuBase Therapeutics' board of directors comprises two types of representatives: NeuBase Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeuBase. The board's role is to monitor NeuBase Therapeutics' management team and ensure that shareholders' interests are well served. NeuBase Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeuBase Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Todd Branning, CFO Secretary | ||
| Dietrich Stephan, President CEO, Director | ||
| Curt Bradshaw, Chief Officer | ||
| Robert Zamboni, Chief Board | ||
| Alan JD, G Counsel | ||
| Ron MBA, Sr Devel | ||
| Shannon McCarthy, Chief Officer |
NeuBase Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NeuBase Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.93 | |||
| Return On Asset | -0.43 | |||
| Current Valuation | (5.83 M) | |||
| Shares Outstanding | 3.75 M | |||
| Shares Owned By Insiders | 13.37 % | |||
| Shares Owned By Institutions | 12.68 % | |||
| Number Of Shares Shorted | 15.57 K | |||
| Price To Earning | (4.17) X | |||
| Price To Book | 0.18 X | |||
| EBITDA | (32.49 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in NeuBase Stock
If you are still planning to invest in NeuBase Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeuBase Therapeutics' history and understand the potential risks before investing.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |